Parion Sciences

Parion Sciences is a private, development-stage biotech company founded in 2000, focusing on novel small molecule therapies for respiratory diseases characterized by impaired mucosal clearance. The company's lead platform involves ENaC (epithelial sodium channel) blockers, designed to hydrate airway surfaces and restore innate defense, with its most advanced candidate, idrevloride, having completed Phase 2 trials for conditions like primary ciliary dyskinesia (PCD). Parion is leveraging its expertise in epithelial biology to expand its pipeline into new mechanisms and indications, positioning itself in the attractive but competitive orphan respiratory disease market. The company operates as a pre-revenue entity, advancing its programs through clinical development and regulatory designations.

Platform focused on epithelial biology and ion channel modulation, specifically epithelial sodium channel (ENaC) blockers designed to hydrate airway surfaces and restore innate mucosal defense. Also exploring targeted pulmonary aerosol delivery (tPAD) and mucolytic agents.

Parion competes in the niche but growing field of mucoactive and host-directed therapies for respiratory diseases. Potential competitors include other companies developing ENaC inhibitors (e.g., Vertex Pharmaceuticals historically), as well as those focused on PCD and bronchiectasis. The standard of care in cystic fibrosis is dominated by CFTR modulators, which may limit the near-term market for ENaC blockers in that indication.